Company intelligence / Profile preview

NeuroSigma

Los Angeles, California, United Statesneurosigma.com ↗

Ownership: Private
Development stage: Commercial

Overview

NeuroSigma's Monarch eTNS System has FDA clearance as a non-drug monotherapy for pediatric ADHD. The company has also received Breakthrough Device Designation from the FDA for drug-resistant epilepsy. Early clinical data suggest efficacy in additional neurodevelopmental disorders such as ASD and dyslexia. The system has CE Mark approval in Europe for adjunctive treatment of epilepsy and major depressive disorder. No serious adverse events have been reported with use of their devices.

Therapeutic areas: Metabolic DisordersPsychiatryNeurology
Modalities: DeviceNon-pharmacological therapyNeuromodulation device (Trigeminal nerve stimulation)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Monarch eTNS System

Commercial

Indications: ADHD

Partnerships

Ignis Groupacademic collaborations with UCLA

Beyond the preview

Go deeper on NeuroSigma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroSigma.

Explore the full profile